NEW YORK, March 9, 2026, 09:36 EDT
- Xenon’s Phase 3 X-TOLE2 trial testing azetukalner in focal onset seizures hit its primary endpoint, the company said.
- The company said it’s eyeing a U.S. FDA filing for the third quarter of 2026.
- Premarket trading saw shares surge following the release of the data update.
Xenon Pharmaceuticals Inc reported Monday that its experimental epilepsy drug azetukalner reduced monthly focal onset seizures in a late-stage study, sparking a jump of over 40% in the stock before the bell. William Blair’s Myles Minter, in a note to clients, described the results as “unprecedented.” Investors
Xenon is feeling the heat as it waits to see if azetukalner can deliver enough for an approval push this year. That window is now off the table: the company says it’s aiming to file its New Drug Application (NDA) in the third quarter of 2026.
Azetukalner targets Kv7 potassium channels, holding them open to dial down overactive nerve firing. Xenon is pushing this candidate in both epilepsy and depression, though the seizure trial is front and center for now.
Xenon reported that in X-TOLE2, patients receiving the 25 mg dose saw a 53.2% median drop in monthly seizure frequency across 12 weeks. Placebo patients got a 10.4% cut. The 15 mg group posted a 34.5% decrease, according to the company.
Ian Mortimer, the chief executive, said the company’s priorities now turn to filing with the FDA and starting “commercial-readiness activities” as Xenon prepares for what could be its debut launch. Xenon Pharma
Jacqueline A. French, neurologist at NYU Langone Health and chairing the trial’s steering committee, pointed to the “differentiated clinical profile” shown by azetukalner. She noted the convenience of once-daily dosing and said titration isn’t required. Yahoo Finance
Xenon reported that azetukalner was mostly well tolerated, noting dizziness turned up most often among treatment-emergent side effects. According to the company, more patients in the 25 mg cohort dropped out due to adverse events compared to those on placebo.
Some analysts called the update a reset for expectations. Stifel analysts described the numbers as a “best-case scenario,” noting that investors are likely to rethink their assumptions about uptake and peak sales. BioSpace
Plenty of competition here. Praxis Precision Medicines and Rapport Therapeutics both have clinical programs underway in focal epilepsy—a field still ruled by established antiseizure drugs that often deliver only partial seizure control for patients.
But nothing’s guaranteed from here. The FDA might challenge the chosen dose, request stricter safety labeling, or demand clearer proof that the benefit tops what’s already on the market. And when a drug moves out into broader use, tolerability sometimes doesn’t match up with trial data.
Xenon plans to deliver the X-TOLE2 results during a late-breaking oral session at the American Academy of Neurology meeting in April. The company held an investor call Monday morning.
